How should we assess the value of innovative drugs in oncology? Lessons from cost-effectiveness analyses.
作者信息
Prasad Vinay, Mailankody Sham
机构信息
Medical Oncology Service, National Cancer Institute, National Institutes of Health, Bethesda, MD Hematology-Oncology Service, Knight Cancer Center, Oregon Health & Sciences University, Portland, OR.
Medical Oncology Service, National Cancer Institute, National Institutes of Health, Bethesda, MD Myeloma Service, Division of Hematologic Malignancies, Memorial Sloan Kettering Cancer Center, New York, NY.
出版信息
Blood. 2015 Oct 8;126(15):1860-1. doi: 10.1182/blood-2015-07-657478. Epub 2015 Aug 28.
Abstract
摘要
相似文献
1
How should we assess the value of innovative drugs in oncology? Lessons from cost-effectiveness analyses.我们应如何评估肿瘤学创新药物的价值？成本效益分析的经验教训。
Blood. 2015 Oct 8;126(15):1860-1. doi: 10.1182/blood-2015-07-657478. Epub 2015 Aug 28.
2
Value of innovation in hematologic malignancies: a systematic review of published cost-effectiveness analyses.血液系统恶性肿瘤创新的价值：已发表的成本效益分析的系统评价
Blood. 2015 Mar 19;125(12):1866-9. doi: 10.1182/blood-2014-07-592832. Epub 2015 Feb 5.
3
Therapy for Hematologic Cancers in Older Patients, Quality of Life, and Health Economics: Difficult Decisions.老年血液系统癌症的治疗、生活质量与卫生经济学：艰难抉择
JAMA Oncol. 2015 Aug;1(5):571-2. doi: 10.1001/jamaoncol.2015.1084.
4
Considerations for Cost-effectiveness Analysis of Curative Pediatric Therapies.儿科治疗性疗法成本效益分析的考量因素
JAMA Pediatr. 2018 May 1;172(5):409-410. doi: 10.1001/jamapediatrics.2018.0049.
5
Pharmacoeconomic analyses make way into oncology.药物经济学分析进入肿瘤学领域。
J Natl Cancer Inst. 2000 Aug 2;92(15):1204-5. doi: 10.1093/jnci/92.15.1204.
6
Long-term effectiveness and cost-effectiveness of an 18-week supervised exercise program in patients treated with autologous stem cell transplantation: results from the EXIST study.自体干细胞移植治疗患者 18 周监督下运动方案的长期效果和成本效益：来自 EXIST 研究的结果。
J Cancer Surviv. 2019 Aug;13(4):558-569. doi: 10.1007/s11764-019-00775-9. Epub 2019 Jul 8.
7
Value of innovation for hematologic malignancies.
J Med Econ. 2016;19(5):487-9. doi: 10.3111/13696998.2015.1133429. Epub 2016 Jan 11.
8
Value assessment in oncology drugs: funding of drugs for metastatic breast cancer in Canada.肿瘤药物的价值评估：加拿大转移性乳腺癌药物的资金投入
Curr Oncol. 2018 Jun;25(Suppl 1):S161-S170. doi: 10.3747/co.25.3846. Epub 2018 Jun 13.
9
Are high drug prices for hematologic malignancies justified? A critical analysis.血液系统恶性肿瘤的高药价合理吗？批判性分析。
Cancer. 2015 Oct 1;121(19):3372-9. doi: 10.1002/cncr.29512. Epub 2015 Jun 23.
10
The economic burden of malignant and premalignant hematological diseases in Southern Nigeria.尼日利亚南部恶性及癌前血液疾病的经济负担
Niger J Clin Pract. 2018 Nov;21(11):1396-1402. doi: 10.4103/njcp.njcp_278_18.
引用本文的文献
1
Valuing treatment in oncology: embracing a broader notion of value.重视肿瘤学治疗中的价值：拥抱更广泛的价值观念。
J Manag Care Spec Pharm. 2022 Mar;28(3):362-368. doi: 10.18553/jmcp.2022.21153. Epub 2022 Jan 31.
2
First-Line Atezolizumab Plus Bevacizumab versus Sorafenib in Hepatocellular Carcinoma: A Cost-Effectiveness Analysis.一线阿替利珠单抗联合贝伐单抗与索拉非尼治疗肝细胞癌的成本效益分析
Cancers (Basel). 2021 Feb 24;13(5):931. doi: 10.3390/cancers13050931.
3
Cost-effectiveness of Pembrolizumab as a Second-Line Therapy for Hepatocellular Carcinoma.帕博利珠单抗作为二线治疗肝细胞癌的成本效益。
JAMA Netw Open. 2021 Jan 4;4(1):e2033761. doi: 10.1001/jamanetworkopen.2020.33761.
4
The economic impact of the transition from branded to generic oncology drugs.肿瘤药物从品牌药到仿制药转换的经济学影响。
Curr Oncol. 2019 Apr;26(2):89-93. doi: 10.3747/co.26.4395. Epub 2019 Apr 1.
5
Cancer drug development: The missing links.癌症药物研发：缺失的环节。
Exp Biol Med (Maywood). 2019 May;244(8):663-689. doi: 10.1177/1535370219839163. Epub 2019 Apr 8.
6
The high price of anticancer drugs: origins, implications, barriers, solutions.抗癌药物的高昂价格：起源、影响、障碍、解决方案。
Nat Rev Clin Oncol. 2017 Jun;14(6):381-390. doi: 10.1038/nrclinonc.2017.31. Epub 2017 Mar 14.
7
Treatment of newly diagnosed myeloma: Bortezomib-based triplet.新诊断骨髓瘤的治疗：基于硼替佐米的三联疗法。
Semin Oncol. 2016 Dec;43(6):700-702. doi: 10.1053/j.seminoncol.2016.11.003. Epub 2016 Nov 5.
本文引用的文献
1
Pricing in the Market for Anticancer Drugs.抗癌药物市场的定价
J Econ Perspect. 2015;29(1):139-62. doi: 10.1257/jep.29.1.139.
2
Value of innovation in hematologic malignancies: a systematic review of published cost-effectiveness analyses.血液系统恶性肿瘤创新的价值：已发表的成本效益分析的系统评价
Blood. 2015 Mar 19;125(12):1866-9. doi: 10.1182/blood-2014-07-592832. Epub 2015 Feb 5.
3
Cost-effectiveness of targeted therapy with cetuximab in patients with K-ras wild-type colorectal cancer presenting with initially unresectable metastases limited to the liver in a German setting.在德国环境下，针对 K-ras 野生型结直肠癌患者肝内初始不可切除转移的靶向治疗药物西妥昔单抗的成本效益分析。
Clin Ther. 2011 Apr;33(4):482-97. doi: 10.1016/j.clinthera.2011.04.010.
4
Rituximab maintenance treatment of relapsed/resistant follicular non-Hodgkin's lymphoma: long-term outcome of the EORTC 20981 phase III randomized intergroup study.利妥昔单抗维持治疗复发/难治性滤泡性非霍奇金淋巴瘤：EORTC 20981 期随机分组研究的长期结果。
J Clin Oncol. 2010 Jun 10;28(17):2853-8. doi: 10.1200/JCO.2009.26.5827. Epub 2010 May 3.
5
Cost-effectiveness of extended adjuvant rituximab for US patients aged 65-70 years with follicular lymphoma in second remission.对于处于第二次缓解期的65 - 70岁美国滤泡性淋巴瘤患者，延长辅助使用利妥昔单抗的成本效益分析。
Clin Lymphoma Myeloma. 2008 Jun;8(3):166-70. doi: 10.3816/CLM.2008.n.020.
6
Rituximab maintenance improves clinical outcome of relapsed/resistant follicular non-Hodgkin lymphoma in patients both with and without rituximab during induction: results of a prospective randomized phase 3 intergroup trial.利妥昔单抗维持治疗可改善复发/难治性滤泡性非霍奇金淋巴瘤患者的临床结局，无论诱导治疗期间是否使用过利妥昔单抗：一项前瞻性随机3期组间试验的结果
Blood. 2006 Nov 15;108(10):3295-301. doi: 10.1182/blood-2006-05-021113. Epub 2006 Jul 27.
7
Bias in published cost effectiveness studies: systematic review.已发表的成本效益研究中的偏倚：系统评价
BMJ. 2006 Mar 25;332(7543):699-703. doi: 10.1136/bmj.38737.607558.80. Epub 2006 Feb 22.
Zotero 插件